Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FT596 |
| Synonyms | |
| Therapy Description |
FT596 consists of induced pluripotent stem cell (iPSC)-derived natural killer cells engineered to express a CD19 targeting chimeric antigen receptor (CAR), a fusion protein consisting of IL15 and IL-15R alpha, and CD16, which may lead to enhanced cytotoxicity in CD19-expressing tumor cells (Blood (2019) 134 (Supplement_1): 301). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FT596 | FT-596|FT 596 | CD19 Immune Cell Therapy 72 | FT596 consists of induced pluripotent stem cell (iPSC)-derived natural killer cells engineered to express a CD19 targeting chimeric antigen receptor (CAR), a fusion protein consisting of IL15 and IL-15R alpha, and CD16, which may lead to enhanced cytotoxicity in CD19-expressing tumor cells (Blood (2019) 134 (Supplement_1): 301). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|